Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calcium-dependent secretion activator 1 (CADPS)
- Target
- CADPS
- Molecular classification
- Other (neural/endocrine-specific cytosolic and peripheral membrane protein), Secretory vesicle-associated protein, Peripheral membrane protein
01
Overview
Calcium-dependent secretion activator 1 (CADPS or CAPS1) is a neural and endocrine-specific cytosolic and peripheral membrane protein required for Ca2+-regulated exocytosis of secretory vesicles, including large dense-core vesicles containing neurotransmitters and neuropeptides. It participates in the priming and fusion of these vesicles with the plasma membrane, functioning after ATP-dependent priming and involving phosphatidylinositol 4,5-bisphosphate synthesis. CADPS1 is part of the CAPS protein family, which also includes CADPS2, and plays a key role in central neurotransmitter systems and neuropeptide regulation, notably catecholamine and dopamine release. Dysregulation or mutation in CADPS family proteins can affect neuronal function and has been implicated in neurodevelopmental disorders and neurodegenerative disease.
- Other names
- CAPS1CAPSCalcium-dependent activator protein for secretion 1KIAA1121UNC-31CADPS1CAPS-1Ca2+-dependent activator protein for secretionCa2+-regulated cytoskeletal protein
02
Mechanism of action
Drugs theoretically acting on CADPS would modulate CA2+-dependent exocytosis, possibly altering neurotransmitter or peptide release. Not a direct drug target in current pharmacology.
03
Biological functions
Exocytosis of secretory vesiclesCa2+-regulated neurotransmitter and neuropeptide releaseCatecholamine loading into dense-core vesicles (DCVs)Regulated secretion of dense-core vesiclesActivity-dependent priming of exocytosisBiogenesis or maintenance of mature secretory vesicles
04
Disease associations
Neurodegenerative disease (e.g., idiopathic Parkinson’s disease, via dopamine pathway involvement)Neurodevelopmental disorders (e.g., autism spectrum disorder via CADPS2)Jejunal SomatostatinomaProstate cancerImpaired development and function of hippocampal GABAergic systems (shown in CAPS2)
05
Safety considerations
Targeting CADPS/CAPS1 could disrupt regulated neurotransmitter and peptide release, potentially leading to broad neurological or endocrine side effects.High risk of off-target effects given its ubiquitous role in regulated exocytosis in many cell types.
06
Interacting drugs
No approved drugs directly targeting CADPS1; none cited in clinical drug databases as direct interactors.
1 more in the full profile.
07
Biomarkers
CADPS1 itself is not a currently established clinical biomarker for patient selection or therapy monitoring.CADPS2 overexpression/variation has been associated with autism and Parkinson’s disease; CADPS1/CAPS1 is researched, not widely used clinically.
Beyond the preview
Go deeper on Calcium-dependent secretion activator 1 (CADPS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Calcium-dependent secretion activator 1 (CADPS).